News stories about Heat Biologics (NASDAQ:HTBX) have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Heat Biologics earned a coverage optimism score of 0.11 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 47.819373275446 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the headlines that may have impacted Accern’s scoring:
Shares of NASDAQ HTBX traded down $0.12 during midday trading on Friday, reaching $1.19. The stock had a trading volume of 164,781 shares, compared to its average volume of 345,012. The stock has a market cap of $7.42, a PE ratio of -0.17 and a beta of 1.02. Heat Biologics has a 12-month low of $1.09 and a 12-month high of $8.50.
Separately, ValuEngine raised shares of Heat Biologics from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 24th.
COPYRIGHT VIOLATION NOTICE: This piece was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/04/08/heat-biologics-htbx-earning-somewhat-favorable-media-coverage-report-shows.html.
Heat Biologics Company Profile
Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.
Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.